Option chain shows key data for Hepion Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Hepion Pharmaceuticals.

Hepion Pharmaceuticals (NASDAQ:HEPA) Stock, Option Chain

Hepion Pharmaceuticals

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Stock Movers

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket

abbott shutter

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ABSI

AGYS

BLBX

LSTA

Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales

Procter & Gamble p&g shutter

Nasdaq Surges 1.5%; Procter &amp; Gamble Posts Upbeat Earnings

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals Inc

Press Releases

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B

Health Care

General

Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

Hepion Pharmaceuticals Announces $9.0 Million Public Offering

Akanda

Artelo Biosciences

Avenue Therapeutics

Eyenovia

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharma

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

SenesTech

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

cbdMD

Comments

Hepion Pharmaceuticals

Hepion Pharmaceuticals (HEPA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga